Radiopharm Theranostics Limited
RADX evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for RADX—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · RADX
Radiopharm Theranostics Limited (RADX) is a clinical-stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic use in high unmet medical need areas, with a pipeline of six licensed platform technologies and a joint venture with MD Anderson.
Key risk: Operating losses and no revenue
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Jun 30, 2025.
Tracking 7 clinical trials · 1 catalyst for Radiopharm Theranostics Limited.
Radiopharm Theranostics Limited (RADX) is a clinical-stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic use in high unmet medical need areas, with a pipeline of six licensed platform technologies and a joint venture with MD Anderson.
- Clinical-stage radiotherapeutics company focused on theranostic products for solid tumors with high mortality rates [sec · filed 2025-09-18].
- Pipeline includes six licensed platform technologies and a joint venture with MD Anderson (Radiopharm Ventures LLC) [sec · filed 2025-09-18].
- Cash and cash equivalents of A$29.1M as of June 30, 2025, expected to fund operations through fiscal 2026 [sec · filed 2025-09-18].
- Accumulated losses of A$145.73M as of June 30, 2025, with a total comprehensive loss of A$37.88M for the fiscal year [sec · filed 2025-09-18].
- No current product revenue; expects to incur significant losses for the foreseeable future [sec · filed 2025-09-18].
What works
- Company has a track record of successful capital raises, providing confidence in ability to secure funding if required [sec · filed 2025-09-18].
- Pipeline includes multiple licensed platform technologies and a joint venture with a leading cancer research center (MD Anderson) [sec · filed 2025-09-18].
- Company intends to pursue FDA approval for all product candidates, with clinical trials structured to be FDA compliant [sec · filed 2025-09-18].
What to weigh
- History of operating losses with accumulated losses of A$145.73M as of June 30, 2025, and no product revenue [sec · filed 2025-09-18].
- Expects to require substantial additional funds to complete R&D; current cash only sufficient through fiscal 2026 [sec · filed 2025-09-18].
- Drug development is subject to numerous risks including regulatory disagreements, need for additional trials, and potential inability to enroll patients [sec · filed 2025-09-18].
From the filings
Quoted directly from source documents.
Company is a clinical-stage radiotherapeutics company
“We are a clinical-stage radiotherapeutics company that focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need.”
SEC filings · September 18, 2025
Cash position as of June 30, 2025
“As of June 30, 2025, we had cash and cash equivalents of A$29,116,835.”
SEC filings · September 18, 2025
Accumulated losses as of June 30, 2025
“As of June 30, 2025, we had accumulated losses of A$145.73 million.”
SEC filings · September 18, 2025
No product revenue and expectation of continued losses
“We currently have no source of product revenue and may never become profitable.”
SEC filings · September 18, 2025
Catalyst timeline
- 2026-10-30 · Phase 1 Start for NTH-2403 — A Phase 1, multicenter study of the safety and imaging of NTH-2403, a Lutetium-177 radiolabeled mono, is scheduled to begin.
Risks & what to watch (3)›
Key risks
- Operating losses and no revenue — History of operating losses, accumulated losses of A$145.73M as of June 30, 2025, and no product revenue [sec · filed 2025-09-18].
- Need for additional financing — Current cash sufficient only through fiscal 2026; substantial additional funds required for long-term goals [sec · filed 2025-09-18].
- Clinical and regulatory uncertainty — Drug development subject to risks including regulatory disagreements, need for additional trials, and patient enrollment difficulties [sec · filed 2025-09-18].
What to watch
- Cash runway and ability to raise additional capital beyond fiscal 2026 [sec · filed 2025-09-18].
- Progress of clinical trials for product candidates, including any FDA interactions [sec · filed 2025-09-18].
- Advancement of the MD Anderson joint venture (Radiopharm Ventures LLC) [sec · filed 2025-09-18].
- Initiation of the Phase 1 study for NTH-2403 (Lutetium-177 radiolabeled mono) expected on 2026-10-30 [upcoming catalysts].
Sources: SEC filings · Generated August 29, 2026 · How we verify sources →
Run Radiopharm Theranostics Limited through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Radiopharm Theranostics Limited facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
Cash runway data unavailable
D/E 1.02
No tracked pipeline phase
No tracked pipeline candidates
1 upcoming, next in ~61d
No insider transactions in the last 180 days
Catalysts
Regulatory
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
5
Total value held
$1.3M
| Holder | Shares | Value |
|---|---|---|
| silverarc capital management, llc | 187,406 | $806K |
| hsbc holdings plc | 61,372 | $265K |
| regal partners ltd | 40,138 | $173K |
| pnc financial services group, inc. | 16,000 | $69K |
| rhumbline advisers | 121 | $519 |
Short Interest
as of May 22, 2026- % of float
- 0.6%
- Days to cover
- 1.0
- Shares short
- 35,793
- Daily short volume
- -
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
RADX short interestFrequently asked questions
What is the AI investment thesis for Radiopharm Theranostics Limited?
Radiopharm Theranostics Limited (RADX) is a clinical-stage radiotherapeutics company developing radiopharmaceutical products for diagnostic and therapeutic use in high unmet medical need areas, with a pipeline of six licensed platform technologies and a joint venture with MD Anderson.
What is Radiopharm Theranostics Limited's next catalyst?
Radiopharm Theranostics Limited's next tracked catalyst is a Phase1_Start event — "Phase 1 Start: A Phase 1, Multicenter Study of the Safety and Imaging of NTH-2403, a Lutetium-177 Radiolabeled Mono" — expected October 30, 2026.
Who is the CEO of Radiopharm Theranostics Limited?
Mr. Riccardo Canevari is the chief executive officer of Radiopharm Theranostics Limited (RADX).
Where is Radiopharm Theranostics Limited headquartered?
Radiopharm Theranostics Limited (RADX) is headquartered in Carlton, VIC, Australia.
What therapeutic areas does Radiopharm Theranostics Limited focus on?
Radiopharm Theranostics Limited develops therapies across Oncology, Dermatology.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.